Look for Post-MI Patients Who May Benefit From an Aldosterone Antagonist
You'll hear more buzz about starting an aldosterone antagonist (spironolactone, eplerenone) in eligible post-MI patients.
This isn't new information. We know adding an aldosterone antagonist to post-MI patients with "systolic" heart failure...or HFrEF...reduces mortality. But less than 20% of patients are started on one.
Help close the gap.